| Name | Title | Contact Details |
|---|
Avigen, Inc. is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since its beginning in 2007 as a technical staffing and business solutions group in Annapolis, Md., Syndicus has evolved into a highly respected technical staffing and consulting solutions group that provides talent and solutions for three focus areas: Health Information Technology, Life Sciences Solutions and Technology Services. We pride ourselves in partnering with top subject matter experts who ensure candidates, consultants and solutions meet clients' specialized needs. In 2012, Syndicus achieved both a full national accreditation with the Management Services Organization Accreditation Program (MSOAP) from the Electronic Healthcare Network Accreditation Commission (EHNAC) and the MSO State Designation from the Maryland Health Care Commission (MHCC). The two certifications enable Syndicus and its electronic health records (EHR) hosted solutions provider eCast Corporation to continue working with Maryland healthcare providers on EHR adoption efforts – and subsequent achievement of Meaningful Use.
Stonegate Community Health Centre is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Natchez Regional Medical Center is a Natchez, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.